Given that BAFF-targeting drugs (e.g., Belimumab and Atacicept) are already approved for the treatment of autoimmune diseases like SLE, this finding suggests that these therapies could potentially be repurposed or expanded to treat other conditions where module 1 is upregulated.19 Here, TNFSF13B is linked to systemic lupus erythematosus.